New study highlights infection as leading cause of death in CAR T therapy recipients
Chicago, IL: Infection emerges as the leading cause of nonrelapse death among patients undergoing CAR T therapy, a groundbreaking treatment revolutionizing cancer care. This therapy, which involves genetically engineering a patient’s own immune cells to target and destroy cancer cells, has shown remarkable success in some cases. However, the risks of infection leading to mortality highlight the importance of ongoing research and development in this field. Recent studies have highlighted the vulnerability of patients undergoing …